270 related articles for article (PubMed ID: 31574517)
21. Systematic Literature Review and Meta-Analysis of Sacral Neuromodulation (SNM) in Patients with Neurogenic Lower Urinary Tract Dysfunction (nLUTD): Over 20 Years' Experience and Future Directions.
van Ophoven A; Engelberg S; Lilley H; Sievert KD
Adv Ther; 2021 Apr; 38(4):1987-2006. PubMed ID: 33713279
[TBL] [Abstract][Full Text] [Related]
22. Long-term results of sacral neuromodulation with the tined lead procedure.
Marcelissen TA; Leong RK; de Bie RA; van Kerrebroeck PE; de Wachter SG
J Urol; 2010 Nov; 184(5):1997-2000. PubMed ID: 20850820
[TBL] [Abstract][Full Text] [Related]
23. Affective symptoms and quality of life in patients with voiding or storage dysfunction: Results before and after sacral neuromodulation: A prospective follow-up study.
Jairam R; Drossaerts J; Vrijens D; Leue C; van Kerrebroeck P; van Koeveringe G
Neurourol Urodyn; 2018 Jun; 37(5):1801-1808. PubMed ID: 29504634
[TBL] [Abstract][Full Text] [Related]
24. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder.
Siegel S; Noblett K; Mangel J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Bennett J; Zylstra S; Berg KC; Kan F; Irwin CP
Neurourol Urodyn; 2015 Mar; 34(3):224-30. PubMed ID: 24415559
[TBL] [Abstract][Full Text] [Related]
25. Detailed Investigation of Bladder Diary Parameters During Sacral Neuromodulation in Patients With Overactive Symptoms.
Van de Borne S; Tilborghs S; Vaganée D; Vermandel A; De Wachter S
Neuromodulation; 2023 Dec; 26(8):1831-1835. PubMed ID: 36266179
[TBL] [Abstract][Full Text] [Related]
26. What Is New in Neuromodulation?
Moore CK; Rueb JJ; Derisavifard S
Curr Urol Rep; 2019 Aug; 20(9):55. PubMed ID: 31388779
[TBL] [Abstract][Full Text] [Related]
27. Screening for depression and anxiety in patients with storage or voiding dysfunction: A retrospective cohort study predicting outcome of sacral neuromodulation.
Drossaerts J; Vrijens D; Leue C; Schilders I; Van Kerrebroeck P; van Koeveringe G
Neurourol Urodyn; 2016 Nov; 35(8):1011-1016. PubMed ID: 26351817
[TBL] [Abstract][Full Text] [Related]
28. Role of sacral neuromodulation in modern urogynaecology practice: a review of recent literature.
Tahseen S
Int Urogynecol J; 2018 Aug; 29(8):1081-1091. PubMed ID: 29302716
[TBL] [Abstract][Full Text] [Related]
29. Sacral Neuromodulation for Genitourinary Problems.
Banakhar M; Hassouna M
Prog Neurol Surg; 2015; 29():192-9. PubMed ID: 26394134
[TBL] [Abstract][Full Text] [Related]
30. Sacral neuromodulation for the treatment of overactive bladder: systematic review and future prospects.
Tilborghs S; De Wachter S
Expert Rev Med Devices; 2022 Feb; 19(2):161-187. PubMed ID: 35061951
[TBL] [Abstract][Full Text] [Related]
31. Outcomes in a contemporary cohort undergoing sacral neuromodulation using optimized lead placement technique.
Adelstein SA; Lee W; Gioia K; Moskowitz D; Stamnes K; Lucioni A; Kobashi KC; Lee UJ
Neurourol Urodyn; 2019 Aug; 38(6):1595-1601. PubMed ID: 31044466
[TBL] [Abstract][Full Text] [Related]
32. Refractory overactive bladder after urethrolysis for bladder outlet obstruction: management with sacral neuromodulation.
Starkman JS; Duffy JW; Wolter CE; Kaufman MR; Scarpero HM; Dmochowski RR
Int Urogynecol J Pelvic Floor Dysfunct; 2008 Feb; 19(2):277-82. PubMed ID: 17671752
[TBL] [Abstract][Full Text] [Related]
33. Analysis of the Correlation Between the Clinical Effect of Sacral Neuromodulation and Patient Age: A Retrospective Multicenter Study in China.
Meng L; Zhang W; Zhang Y; Wang J; Liao L; Chen G; Ling Q; Zhang P; Wei Z; Chen Q
Neuromodulation; 2020 Dec; 23(8):1189-1195. PubMed ID: 32196813
[TBL] [Abstract][Full Text] [Related]
34. Medium-term outcomes of sacral neuromodulation in patients with refractory overactive bladder: A retrospective single-institution study.
Kaaki B; Gupta D
PLoS One; 2020; 15(7):e0235961. PubMed ID: 32645082
[TBL] [Abstract][Full Text] [Related]
35. Preliminary analysis of stimulation parameters for sacral neuromodulation in different indications: a multicenter retrospective cohort study from China.
Meng L; Yan Z; Wang X; Zhang Y; Zhu Z; Zhu W; Ling Q; Sun X; Gu Y; Lv J; Li Y
Int J Surg; 2024 Jun; 110(6):3536-3542. PubMed ID: 38445489
[TBL] [Abstract][Full Text] [Related]
36. The Value of Ambulatory Urodynamics in the Evaluation of Treatment Effect of Sacral Neuromodulation.
Drossaerts J; Rademakers KLJ; Rahnama'i SM; Marcelissen T; Van Kerrebroeck P; van Koeveringe G
Urol Int; 2019; 102(3):299-305. PubMed ID: 30612126
[TBL] [Abstract][Full Text] [Related]
37. Prolonged percutaneous SNM testing does not cause infection-related explanation.
Amend B; Bedke J; Khalil M; Stenzl A; Sievert KD
BJU Int; 2013 Mar; 111(3):485-91. PubMed ID: 22738331
[TBL] [Abstract][Full Text] [Related]
38. Long-term follow-up of sacral neuromodulation for lower urinary tract dysfunction.
Peeters K; Sahai A; De Ridder D; Van Der Aa F
BJU Int; 2014 May; 113(5):789-94. PubMed ID: 24238278
[TBL] [Abstract][Full Text] [Related]
39. Patient preferences for treating refractory overactive bladder in the UK.
Hashim H; Beusterien K; Bridges JF; Amos K; Cardozo L
Int Urol Nephrol; 2015 Oct; 47(10):1619-27. PubMed ID: 26347077
[TBL] [Abstract][Full Text] [Related]
40. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy.
Smits MA; Oerlemans D; Marcelissen TA; Van Kerrebroeck PE; De Wachter SG
J Urol; 2013 Dec; 190(6):2148-52. PubMed ID: 23872028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
